Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor:: Synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2-trifluoroethylsulfonyl)pyrid-3-ylmethyl-amine

被引:168
作者
Johnson, MP [1 ]
Baez, M [1 ]
Jagdmann, GE [1 ]
Britton, TC [1 ]
Large, TH [1 ]
Callagaro, DO [1 ]
Tizzano, JP [1 ]
Monn, JA [1 ]
Schoepp, DD [1 ]
机构
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Indianapolis, IN 46285 USA
关键词
D O I
10.1021/jm034015u
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This report describes recently discovered novel allosteric modulators of metabotropic glutamate2 (mGlu2) receptors. These pyridylmethylsulfonamides (e.g., 3) potentiate glutamate, shifting agonist potency by 2-fold. This effect was specific for mGlu2 (vs mGlu1,3-8 receptors). Also, 3 failed to potentiate a chimeric mGlu2/1 receptor, demonstrating the mGlu2 transmembrane region's critical involvement. In a fear-potentiated startle model, 3 showed anxiolytic activity that was prevented by mGlu2/3 antagonist pretreatment. Thus, these pyridylmethylsulfonamides represent the first mGlu2 receptor potentiators discovered.
引用
收藏
页码:3189 / 3192
页数:4
相关论文
共 25 条
  • [1] Baez M, 2002, NEUROPHARMACOLOGY, V43, P274
  • [2] In vivo inhibition of veratridine-evoked release of striatal excitatory amino acids by the group II metabotropic glutamate receptor agonist LY354740 in rats
    Battaglia, G
    Monn, JA
    Schoepp, DD
    [J]. NEUROSCIENCE LETTERS, 1997, 229 (03) : 161 - 164
  • [3] Britton T, 2002, NEUROPHARMACOLOGY, V43, P279
  • [4] Cartmell J, 1999, J PHARMACOL EXP THER, V291, P161
  • [5] Regulation of neurotransmitter release by metabotropic glutamate receptors
    Cartmell, J
    Schoepp, DD
    [J]. JOURNAL OF NEUROCHEMISTRY, 2000, 75 (03) : 889 - 907
  • [6] DESAI MA, 1995, MOL PHARMACOL, V48, P648
  • [7] Pharmacological characterization of desensitization in a human mGlu1 alpha-expressing non-neuronal cell line co-transfected with a glutamate transporter
    Desai, MA
    Burnett, JP
    Mayne, NG
    Schoepp, DD
    [J]. BRITISH JOURNAL OF PHARMACOLOGY, 1996, 118 (06) : 1558 - 1564
  • [8] Gomeza J, 1996, MOL PHARMACOL, V50, P923
  • [9] Helton DR, 1998, J PHARMACOL EXP THER, V284, P651
  • [10] Johnson K, 2002, NEUROPHARMACOLOGY, V43, P291